Shots:

• Samsung Bioepis reports the expansion of its global business with the entry of its first product- Brenzys (etanercept) in Brazil through Brazil’s public health system- Sistema Único de Saúde (SUS)
• Samsung Bioepis signed a PDP agreement with Bionovis and Bio-Manguinhos/Fiocruz supplying Brenzis for the sales to SUS for a period of 10 years and will transfer its technology to the 2 companies enabling the manufacturing of Brenzys in Brazil 
• Brenzys is a biosimilar of a reference product- Enbrel and has received ANVISA’s approval for RA- PsA- axSpA- AS and plaque Psoriasis in Dec’2017. Samsung Bioepis is expanding its business globally including China and collaborated with 3SBio & C-Bridge Capital to develop and commercialize its biosimilar candidates 

Click here to­ read full press release/ article

 Ref: Samsung Bioepis | Image: Samsung Bioepis